Deferasirox's toxicity

The Lancet

Volumn 382, Issue 9887, 2013, Pages 127-128

  Riva, Alessandro ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE;

CLINICAL TRIAL (TOPIC); CURRICULUM; DRUG APPROVAL; DRUG SAFETY; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; IRON OVERLOAD; KIDNEY DISEASE; LETTER; MORTALITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOCIAL MEDIA;

EID: 84880251758     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61564-0     Document Type: Letter

References (5)

1. GJ Kontoghiorghes Turning a blind eye to deferasirox's toxicity? Lancet 381 2013 1183 1184
2. E Nisbet-Brown, NF Olivieri, PJ Giardina et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 361 2003 1597 1602
3. MD Cappellini, A Cohen, A Piga et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia Blood 107 2006 3455 3462
4. MD Cappellini, JB Porter, A El-Beshlawy et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias Haematologica 95 2010 557 566
5. AT Taher, J Porter, V Viprakasit et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study Blood 120 2012 970 977